Blindsight is Neuralink's proposed visual prosthesis, a brain implant program intended to create visual perception for people with profound vision loss. The concept is to stimulate brain regions involved in vision, rather than relying entirely on a working eye-to-brain pathway.
Neuralink announced in September 2024 that the US FDA had granted Blindsight a Breakthrough Device designation. That program can provide more interaction with regulators during development, but designation is not proof that the implant restores sight, is safe for routine use or has received permission to be sold.
The company describes a system that would use images captured by a camera and send information to the implant for stimulation of the visual system. The quality of any future percept, its usable field of view and the practical benefit to patients must be established through appropriately designed human studies. These features should not be presented as demonstrated clinical outcomes.
When assessing new Blindsight announcements, separate the proposed mechanism, regulatory milestones, first-in-human data and independently verified functional results. Do not treat the program's name as evidence that natural vision has already been restored.